Please note that following on from information provided to NICE by the company in January 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | HST |
| ID number | 3739 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2025 | Discontinued. Please note that following on from information provided to NICE by the company in January 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 21 March 2023 | Suspended. The company have advised that the European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for Palovarotene to reduce the formation of heterotopic ossification associated with fibrodysplasia ossificans progressiva. Therefore, NICE has decided to suspend this evaluation from its work program until further information is available. As this evaluation has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
| 04 August 2022 | Invitation to participate |
| 14 March 2022 (14:00) | Scoping workshop |
| 18 January 2022 - 15 February 2022 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual